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P
risoners endure some of the 
worst health outcomes and 
are known to engage in var-
ious kinds of health-risk behaviour, 
including substance misuse (eg, inject-
ing drug use), risky sexual behaviour, 
tattooing and violence.1-3
Risky behaviour does not cease on 
entry to prison. About half of injecting 
drug users (IDUs) continue to inject 
illicit drugs while in prison, where 
access to clean injecting equipment 
is the exception.4 Sharing of contam-
inated injecting equipment, tattooing 
and other forms of blood-to-blood 
contact have been implicated in the 
transmission of HIV and hepatitis 
viruses among prison inmates,5 and 
incarceration is associated with prev-
alent and incident HIV infection, hep-
atitis B and hepatitis C, particularly 
among IDUs.6-8
Many prisoners are incarcerated for 
short periods before they are released 
back into the community. Recently 
released IDUs are more likely to report 
sharing syringes compared with IDUs 
who have no history of incarceration.9 
Given the potential for incarcerated 
populations to affect the health of the 
general community, particularly in the 
context of infectious diseases, ongoing 
surveillance of the prisoner popula-
tion to monitor this risk is important.
Here, we report the prevalence of 
exposure to HIV, hepatitis B virus, 
and hepatitis C virus among prisons 
entrants in Australia and describe 
changes between three survey peri-
ods (2004, 2007 and 2010).
Methods
The National Prison Entrants’ 
Bloodborne Virus Survey (NPEBBVS) 
commenced in Australia in 2004 to 
provide ongoing data on infectious 
disease prevalence among people 
entering prisons from the commu-
nity.10 It is a cross-sectional survey 
of prison entrants that has been con-
ducted over 2-week periods in 2004, 
2007 and 2010. Detailed methods are 
published elsewhere.10 Briefl y, prison 
entrants from up to 29 reception pris-
ons across Australia have contributed 
to the survey. Four states contributed 
to the survey in 2004: New South 
Wales, Queensland, Tasmania and 
Western Australia. By 2010, prisons 
in the Australian Capital Territory, the 
Northern Territory, South Australia, 
Tasmania and Victoria also contrib-
uted. The survey was conducted from 
17 May to 30 May in 2004, from 8 
October to 29 October in 2007 and 
from 11 October to 22 November in 
2010. In each jurisdiction, the survey 
was conducted during 2-week periods, 
although the start date of the 2-week 
period differed slightly for some juris-
dictions in 2007 and 2010.
Participants
All new receptions during the sur-
vey periods were invited to partici-
pate. New receptions were defi ned as 
individuals entering prison from the 
community and did not include those 
already in the system and returning 
from court appearances or prisoners 
transiting through the survey sites en 
route to other facilities. Potential par-
ticipants were briefed on the project 
by a reception nurse (with emphasis 
placed on the voluntary nature of the 
study) and provided with a descrip-
tion of the procedures (ie, a short 
questionnaire on risk behaviour fol-
lowed by blood testing). Written con-
sent was required for participation. 
Participants were informed that they 
would receive their test results, with 
appropriate community follow-up and 
referrals if needed. The response rate 
was 77% in 2004, and 76% in 2007 
and 2010.10
Serological markers
Blood testing included screening for 
the following markers: anti-HIV anti-
body (anti-HIV), hepatitis B surface 
antigen (HBsAg), anti-hepatitis B core 
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Abstract
Objective: To report the prevalence of markers for HIV infection, hepatitis B and 
hepatitis C among Australian prison entrants.
Design: Cross-sectional survey conducted over 2-week periods in 2004, 2007 
and 2010.
Setting: Reception prisons in New South Wales, Queensland, Tasmania and 
Western Australia.
Participants: Individuals entering prison from the community during the survey 
periods.
Main outcome measure: Prevalence of anti-HIV antibody (anti-HIV), hepatitis 
B surface antigen (HBsAg), anti-hepatitis B core antibody (anti-HBc) and anti-
hepatitis C virus antibody (anti-HCV).
Results: The study included 1742 prison entrants: 588 (33.8%) in 2004, 536 
(30.8%) in 2007 and 618 (35.5%) in 2010. The age-standardised prevalence 
estimates for anti-HIV, HBsAg and anti-HBc were 0.4%, 2.3% and 21.7% 
respectively, and remained stable over the three survey periods. The age-
standardised prevalence estimate for anti-HCV was 29.0%; it decreased over 
time (33.3% in 2004 v 23.2% in 2010; P = 0.001), and this coincided with a 
decrease in prison entrants reporting injecting drug use (58.3% [343/588] in 
2004 v 45.3% [280/618] in 2010; P < 0.001). Among injecting drug users, the 
prevalence of anti-HCV was 57.2% and did not change signifi cantly over time. 
Of those who were anti-HCV positive, 33.7% (140/415) were unaware of their 
infection status, and 74.3% (185/249) of those who tested positive for anti-HBc 
reported that they had never had hepatitis B.
Conclusions: HIV prevalence is low in the Australian prisoner population but 
transmission remains a risk. Despite a decrease in the proportion of prison 
entrants reporting injecting drug use, prevalence of hepatitis B and hepatitis C 
has remained high. Treatment and prevention initiatives should be prioritised for 
this population.
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antibody (anti-HBc) and anti-hepatitis 
C virus antibody (anti-HCV).
Statistical methods
Only participants from the four states 
that contributed to all iterations of 
the survey were included in the ana-
lysis. As injecting drug use is a key 
risk factor for transmission of many 
bloodborne viruses (BBVs), prison-
ers were excluded from the analysis 
if their injecting drug use status was 
unknown. The sample size differed 
slightly for each serological marker as 
not all participants were successfully 
tested for all four markers.
Crude and age-standardised prev-
alence estimates were calculated 
for anti-HIV, HBsAg, anti-HBc and 
anti-HCV. Age-standardised preva-
lence estimates were calculated using 
the Australian Bureau of Statistics 
Standard Population for Use in Age-
Standardisation Table.
Where a suffi cient number of events 
(> 30) were present, Poisson regres-
sion was used to assess trends over 
time after accounting for potentially 
confounding variables. The follow-
ing demographic and criminological 
factors, collected via the question-
naire, were considered for inclusion 
in the multivariate models: sex, age, 
Indigenous status, region of birth 
(Australia, Asia, other Oceania, and 
other or unknown), sexual identity, 
tattoos, injecting drug use, number of 
times in prison, jurisdiction of prison, 
and postcode in which the partici-
pant had spent the most time before 
entering prison. Postcodes were clas-
sifi ed according to the Accessibility/
Remoteness Index of Australia and cat-
egorised as “highly accessible” or “not 
highly accessible”.11
Logistic regression was used to 
assess factors associated with having 
previously been tested for HIV or hep-
atitis C. Stepwise selection was used to 
develop the multivariate model; a sig-
nifi cance level of 0.5 was used for entry 
and retention in the model.
Analyses were performed using 
SAS 9.3 (SAS Institute) and Stata 12 
(StataCorp).
Ethics approval
Approval for the project was obtained 
from the human research and ethics 
committees in the ACT, NSW, SA, Tas 
and WA. In addition to the health-
based ethics committees, approval was 
sought separately from the corrective 
services’ ethics committees in NSW, 
QLD, Vic and WA. In WA, approval 
was granted by the Western Australia 
Aboriginal Health and Information 
Ethics Committee. The study was also 
approved by the Curtin University of 
Technology Human Research Ethics 
Committees.
Results
During the survey periods, an esti-
mated 2247 individuals entered prison 
in NSW, Qld, Tas and WA; 1742 (77.5%) 
completed the study questionnaire and 
were included in the analysis (588 
[33.8%] in 2004, 536 [30.8%] in 2007 
and 618 [35.5%] in 2010). Most partic-
ipants were men (1567; 90.0%), aged 
 25 years (1249; 71.7%), heterosexual 
(1680; 96.4%), and born in Australia 
(1438; 82.5%). About half of the par-
ticipants had previously injected drugs 
(914; 52.5%) (Appendix 1; all appendi-
ces online at mja.com.au).
Of the 1394 participants who were 
tested for anti-HIV, seven tested pos-
itive, giving an overall age-stan-
dardised prevalence of anti-HIV of 
0.4% (Box). The age-standardised 
prevalence of anti-HIV did not vary 
signifi cantly between 2004 and 2007 
(P = 0.70). Due to the small number of 
events, no multivariate analysis was 
undertaken.
The overall age-standardised preva-
lence of HBsAg was 2.3%; there was a 
non-signifi cant decrease from 2.8% in 
Crude and age-standardised prevalence estimates for anti-HIV, HBsAg, anti-HBc and anti-HCV among prisoners in New South Wales, Queensland, 
Tasmania and Western Australia, overall and by injecting drug use status — 2004, 2007, 2010
Overall prevalence (95% CI) Prevalence among IDUs (95% CI) Prevalence among non-IDUs (95% CI)
No. tested No. positive Crude Age-standardised Crude Age-standardised Crude Age-standardised
Anti-HIV
Total 1394 7 0.5% 0.4% (0.1%–0.6%) 0.7% 0.4% (0.1%–0.7%) 0.3% 0.3% (0.0%–0.7%)
2004 436 3 0.7% 0.6% (0.0%–1.4%) 0.8% 0.4% (0.0%–1.0%) 0.6% 0.7% (0.0%–2.1%)
2007 437 4 0.9% 0.6% (0.0%–1.1%) 0.9% 0.6% (0.0%–1.3%) 0.5% 0.2% (0.0%–0.6%)
2010 521 0 0 — 0 — 0 —
HBsAg
Total 1388 31 2.2% 2.3% (1.4%–3.2%) 3.0% 3.1% (1.5%–4.7%) 1.4% 1.4% (0.4%–2.4%)
2004 440 13 3.0% 2.8% (1.1%–4.4%) 5.0% 4.7% (1.9%–7.6%) 0 —
2007 438 10 2.3% 2.3% (0.7%–3.9%) 2.9% 3.0% (0.3%–5.6%) 1.5% 1.2% (0.0%–2.7%)
2010 510 8 1.6% 1.9% (0.4%–3.3%) 0.9% 0.6% (0.0%–1.5%) 2.1% 2.6% (0.4%–4.8%)
Anti-HBc
Total 1285 249 19.4% 21.7% (19.1%–24.3%) 25.3% 29.7% (24.7%–34.6%) 12.7% 14.6% (11.4%–17.7%)
2004 433 85 19.6% 21.4% (17.0%–25.7%) 26.9% 33.3% (24.2%–42.4%) 9.4% 10.5% (5.7%–15.2%)
2007 441 91 20.6% 22.6% (18.0%–27.1%) 29.1% 37.9% (31.5%–44.3%) 10.5% 11.6% (6.6%–16.6%)
2010 411 73 17.8% 20.7% (16.2%–25.3%) 18.4% 17.3% (11.8%–22.7%) 17.3% 21.5% (15.2%–27.7%)
Anti-HCV
Total 1393 415 29.8% 29.0% (26.4%–31.6%) 55.6% 57.2% (52.6%–61.9%) 2.2% 2.7% (1.2%–4.2%)
2004 440 151 34.3% 33.3% (28.6%–37.9%) 56.6% 62.3% (54.7%–69.8%) 3.3% 4.0% (0.8%–7.2%)
2007 437 145 33.2% 31.6% (26.8%–36.4%) 57.7% 59.3% (50.9%–67.6%) 3.5% 4.0% (0.6%–7.3%)
2010 516 119 23.1% 23.2% (19.3%–27.1%) 52.0% 51.9% (43.8%–59.9%) 0.7% 0.9% (0.0%–2.2%)
Anti-HIV = anti-HIV antibody. HBsAg = hepatitis B surface antigen. Anti-HBc = anti-hepatitis B core antibody. Anti-HCV = anti-hepatitis C virus antibody. IDUs = injecting drug users.
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2004 to 1.9% in 2010 (P = 0.15). In the 
multivariate analysis, the risk of test-
ing positive for HBsAg did not vary 
signifi cantly between 2004 and 2007 
(P = 0.51) or between 2004 and 2010 
(P = 0.19). Factors associated with an 
increased risk of testing positive for 
HBsAg included being born in Oceania 
(excluding Australia) (P = 0.03) or 
Asia (P < 0.001), being Indigenous 
(P = 0.003), and having ever injected 
drugs (P = 0.04) (Appendix 2).
The overall age-standardised prev-
alence of anti-HBc was 21.7% which 
remained stable over time (Box) (2004 
v 2007, P = 0.74; 2004 v 2010, P = 0.53). 
In the multivariate analysis, there was 
no signifi cant difference in the risk of 
testing positive for anti-HBc in 2007 
(P = 0.90) or 2010 (P = 0.75) compared 
with 2004. Participants who were aged 
 25 years (P < 0.001), born in Oceania 
(excluding Australia) (P < 0.001) or 
Asia (P < 0.001) or were Indigenous 
(P < 0.001), and those who had ever 
injected drugs (P < 0.001) or had pre-
viously been in prison (P = 0.01 for 
2–4 times in prison, P = 0.004 for 5–9 
times, P = 0.03 for  10 times), had an 
increased risk of testing positive for 
anti-HBc (Appendix 3). Participants 
in Qld had a lower risk of testing pos-
itive for anti-HBc than those in NSW 
(P < 0.001).
Hepatitis C was the most preva-
lent BBV; 415 participants tested pos-
itive for anti-HCV, giving an overall 
age-standardised prevalence of 29.0% 
(Box). The age-standardised preva-
lence of anti-HCV was similar in 2004 
(33.3%) and 2007 (31.6%) (P = 0.77) and 
lower in 2010 (23.2%) compared with 
2004 (P = 0.001); this coincided with a 
decrease in prison entrants reporting 
injecting drug use (58.3% [343/588] 
in 2004 v 45.3% [280/618] in 2010; 
P < 0.001). However, in the multivari-
ate analysis, there was no signifi cant 
difference in the risk of testing pos-
itive for anti-HCV in 2007 (P = 0.86) 
or 2010 (P = 0.99) compared with 2004 
(Appendix 4).
The predominant factor associated 
with testing positive for anti-HCV was 
injecting drug use (Appendix 4). The 
proportion of participants who had 
ever injected drugs declined over time, 
so the analysis was stratifi ed by inject-
ing drug use status (Box). The overall 
age-standardised prevalence of anti-
HCV among IDUs was 57.2% and this 
did not vary signifi cantly across the 
three survey periods: 62.3% in 2004, 
59.3% in 2007, and 51.9% in 2010 
(P = 0.67). Among non-IDUs the over-
all age-standardised prevalence was 
2.7%, and there was a small decrease 
over time: 4.0% in 2004, 4.0% in 2007, 
and 0.9% in 2010 (P = 0.04).
In addition, participants who were 
women (P = 0.05), aged  25 years 
(P = 0.001) or living in highly accessi-
ble areas (P = 0.01), and those who had 
previously been in prison (P = 0.001 for 
2–4 times in prison, P < 0.001 for 5–9 
times, P < 0.001 for  10 times), had an 
increased risk of testing positive for 
anti-HCV (Appendix 4). Participants 
in WA had a lower risk of testing posi-
tive for anti-HCV compared with those 
in NSW (P = 0.003).
Co-infection
One participant, recruited in 2004, 
tested positive for both anti-HIV and 
anti-HCV, but no participants tested 
positive for both anti-HIV and anti-
HBc. Of 1271 participants who were 
tested for anti-HBc and anti-HCV, 131 
(10.3%) tested positive for both (51 in 
2004, 52 in 2007, 28 in 2010). Thirteen 
participants tested positive for both 
anti-HCV and HBsAg (six in 2004, fi ve 
in 2007, two in 2010).
Self-reporting versus serological 
testing
In the questionnaire, 1173 partici-
pants (67.3%) reported that they had 
been tested for HIV (626 [35.9%] in the 
past year) and 1150 (66.0%) reported 
that they had been tested for hepa-
titis C (595 [34.2%] in the past year). 
One participant who tested positive 
for anti-HIV was aware of their HIV 
status, 64 of those who tested positive 
for anti-HBc (25.7%) reported that they 
had been infected with HBV and 275 
of those who tested positive for anti-
HCV (66.3%) reported that they had 
had hepatitis C.
Those more likely to have had a 
previous test for HIV and/or hepa-
titis C were: women (adjusted odds 
ratio [AOR], 2.47; 95% CI, 1.51–4.05; 
P < 0.001), aged  25 years (AOR, 
2.00; 95% CI, 1.54–2.59; P < 0.001), 
homosexual or bisexual (AOR, 10.65; 
95% CI, 2.34–48.50; P = 0.002) and 
IDUs (AOR, 3.99; 95% CI, 3.06–5.20; 
P < 0.001). Also, participants recruited 
in 2007 were more likely to have previ-
ously been tested than those recruited 
in 2004 (AOR, 1.54; 95% CI, 1.13–2.10; 
P = 0.006). However, no signifi cant dif-
ference was observed between 2004 
and 2010 (AOR, 1.24; 95% CI, 0.93–
1.68; P = 0.14). Participants who had 
been in prison 2–4 times (AOR, 1.90; 
95% CI, 1.45–2.50; P < 0.001) and  5 
times (AOR, 5.62; 95% CI, 3.63–8.72; 
P < 0.001) were more likely to have 
been tested than fi rst-time prison 
entrants.
Discussion
The NPEBBVS included about 80% of 
people entering prisons in Australia 
during 2-week periods in 2004, 2007 
and 2010. Overall, the prevalence 
of HIV was low. However, despite a 
decline in the proportion of prisoners 
who reported injecting drug use, the 
prevalence of hepatitis B and hepa-
titis C remained high among prison 
entrants. Many of those tested were 
unaware of their infection status.
We estimated the overall anti-
HIV prevalence to be 0.4%, which is 
lower than the rates of HIV infection 
among prisoners in North America 
and Europe12,13 but comparable to anti-
HIV prevalence among prisoners in 
the United Kingdom (0.4%).14 This 
refl ects the low anti-HIV prevalence 
among IDUs in Australia (1.5%)15 and 
has been attributed to the early adop-
tion of HIV prevention measures such 
as widespread access to clean inject-
ing equipment, access to methadone, 
and free and anonymous HIV testing.16
We estimated the prevalence of 
HBsAg to be 2.3% and the prevalence 
of anti-HBc to be 21.7%, compared 
with Australian community esti-
mates of 1% and 6.1%, respectively.17,18 
Injecting drug use was associated with 
an increased risk of testing positive 
for HBsAg and anti-HBc. About 50% 
of prison entrants reported a history 
of injecting drug use, among whom 
prevalence of HBsAg was 3.1% and 
prevalence of anti-HBc was 29.7%. 
In comparison, 20% anti-HBc prev-
alence has been reported for IDUs in 
UK prisons.14
Birth in Oceania (excluding 
Australia) and Asia increased the risk 
of testing positive for HBsAg and anti-
HBc, which is consistent with the epi-
demiological data on hepatitis B in 
Australia.19 An increased risk of hep-
atitis B infection was observed among 
Indigenous prison entrants, and is 
Research
280 MJA 200 (5)  ·  17 March 2014
likely due to higher rates in this popu-
lation in the community.20 Vaccination 
is the primary measure used to con-
trol the transmission of hepatitis B and 
uptake among prison entrants should 
be encouraged.
In Australia, the prevalence of anti-
HCV is about 1%–2% and has been 
reported as decreasing in recent years; 
82% of hepatitis C virus infections are 
attributed to injecting drug use.21 In 
our study, one-third of prison entrants 
tested positive for anti-HCV — 55.6% 
of IDUs and 2.2% of non-IDUs. This 
is comparable to estimates from 
the Australian Needle and Syringe 
Program Survey (anti-HCV prevalence 
of 50%–70%),15 and for prisoners in the 
United States (16%–41%)22 and the UK 
(30% for IDUs, 7% overall).14
We estimated that prevalence of 
anti-HCV among prison entrants 
declined from 33.3% in 2004 to 23.2% 
in 2010. However, after accounting for 
injecting drug use, this difference was 
not signifi cant. This fi nding is sup-
ported by studies modelling the hep-
atitis C epidemic in Australia, which 
show that the incidence of new hep-
atitis C infections peaked in 1999.21,23
Self-reported HIV and hepatitis C 
testing rates were over 65% in our 
study. However, one-third of partic-
ipants who were anti-HCV positive 
were unaware of their infection status, 
and three-quarters of those who tested 
positive for anti-HBc reported they had 
never had hepatitis B. These data are 
similar to those from the 1996 NSW 
Inmate Health Survey, in which 35% 
of participants were unaware that they 
were anti-HCV positive and 72% were 
unaware they were anti-HBc positive, 
indicating little change in awareness 
levels over time.24 Women, IDUs, and 
those previously incarcerated were all 
more likely to be aware of their infec-
tion status, suggesting that these 
groups may have increased access to 
health services and testing. Increased 
awareness among those with a history 
of incarceration highlights the impor-
tant role that prisons play in screen-
ing for, treating and preventing BBVs.
There are some limitations to this 
analysis. While the NPEBBVS has 
expanded its coverage to include 
all jurisdictions in Australia, the 
demographic and criminological 
characteristics of prison entrants may 
differ between jurisdictions in ways 
that we are unable to account for. Thus, 
we restricted the analysis to the states 
that were involved in all iterations of 
the survey. Only variables collected in 
the same format at each survey period 
were included, and there may be other 
unmeasured or unknown confound-
ers that we were unable to adjust for.
Testing strategies for BBVs and 
test coverage vary between jurisdic-
tions: Qld, SA and WA use voluntary 
screening, but NSW uses a targeted 
approach. This supports the need for 
ongoing surveillance using a stan-
dardised approach to reliably report 
prevalence. Ideally, surveillance should 
include collection of data on incident 
cases.
In Australia, the full-time prisoner 
population is about 30 000, and about 
50 000 people cycle through the prison 
system annually.25 Prisons are poten-
tially important in the control of BBVs 
in the community given the high num-
ber of people who pass through correc-
tional facilities each year and the high 
prevalence of BBVs in this population.
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